Manuel Hidalgo Medina, M.D., Ph.D.
Medical Oncology
< Back to Search Results

Manuel Hidalgo Medina, M.D., Ph.D.

Medical Oncology

Profile Photo of Manuel Hidalgo Medina, M.D., Ph.D.
Accepts New Patients
Gender: Male
Language: English


Specialties and Expertise


  • Gastrointestinal Oncology
  • Gastrointestinal Malignancy
  • Gastrointestinal Cancer
  • GI Cancer
  • Pancreatic Cancer


Manuel Hidalgo, M.D., Ph.D., is currently the Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine/NewYork-Presbyterian Hospital. Dr. Hidalgo received his M.D. from the University of Navarra in Pamplona, Spain in 1992, and Ph.D. from University Autonoma of Madrid in 1997. He trained in medicine and medical oncology at Hospital "12 de Octubre" in Madrid and at the University of Texas Health Science Center in San Antonio, Texas. He also completed a fellowship program in anticancer drug development at the Institute of Drug Development in San Antonio. Prior to this position, he served as an Assistant Professor of Medicine at the Division of Hematology and Oncology at the University of Texas Health Science Center in San Antonio. In 2001, Dr. Hidalgo relocated to Johns Hopkins University to serve as Director of the Gastrointestinal Oncology Program at the Kimmel Comprehensive Cancer Center, where he also held the title of Associate Professor of Oncology. Dr. Hidalgo became Director of the Clinical Research Program at the Spanish National Cancer Center in 2009 and Vice Director of Translational Research in 2011. In 2015, he became the Chief of the Division of Hematology and Oncology and Director of the Rosenberg Clinical Cancer Center at the Beth Israel Deaconess Medical Center in Boston. Dr. Hidalgo also served as the Theodore W. and Evelyn G. Berenson Professor of Medicine at Harvard Medical School. His main focus  of research has been new drug development in pancreatic cancer. His group popularized the use of Avatar mouse models for cancer research and recently contributed to the development and Federal Drug Administration (FDA) approval of nab-paclitaxel for pancreatic cancer treatment. Dr. Hidalgo’s current research focuses on strategies for personalized medicine and immunotherapy in pancreatic cancer.




Clinical and Academic Positions

  • Assistant Attending Physician - NewYork-Presbyterian Hospital
  • Assistant Professor of Medicine (Interim) - Weill Cornell Medical College, Cornell University

Education and Training

  • M.Sc., Harvard University, 2017
  • Ph.D., Autonomous University of Madrid, Faculty of Medicine (Spain), 1997
  • M.D., University of Navarra Faculty of Medicine (Spain), 1992


Insurance Plans Accepted

The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please contact the physician’s office as they may have individual contracts not included on this site.

* indicates this physician is no longer accepting new patients with this insurance plan.

  • AETNA - Medicare
  • Aetna - Weill Cornell - POS
  • Aetna-NYP - EPO/POS
  • Affinity Access
  • Affinity Health Plan
  • Amida Care
  • Emblem Select Care
  • Empire Blue Cross/Blue Shield - EPO
  • Empire Blue Cross/Blue Shield - HMO
  • Empire Blue Cross/Blue Shield - Mediblue (Senior)
  • Empire Blue Cross/Blue Shield - PPO
  • Empire Blue Cross/Blue Shield HealthPlus
  • Empire Blue Cross/Blue Shield HealthPlus - CHP
  • Fidelis Care
  • GHI - CBP
  • Health First
  • Health Insurance Plan of NY (HIP)
  • Health Insurance Plan of NY (HIP) - Medicaid
  • Health Insurance Plan of NY (HIP) - Medicare
  • Medicare
  • Oxford Health Plans - Freedom
  • Oxford Health Plans - Liberty
  • Oxford Health Plans - Medicare Advantage
  • Oxford Health Plans - Metro/Core/Charter
  • Rockefeller University - Trustmark
  • United Empire
  • United Healthcare
  • United Healthcare - Community Plan
  • United Healthcare - Medicare
  • United Healthcare Compass
  • VNSNY CHOICE - Medicare
  • WellCare of NY

Locations and Appointments